(HealthDay)—The use of patient-reported outcome measures (PROMs) to complement clinician-reported outcomes (CROs) may yield important information for assessing disease severity and guiding treatment of psoriasis, according to a research letter published online Sept. 8 in JAMA Dermatology. John S. Barbieri, M.D., and Joel M. Gelfand, M.D., both from the University of Pennsylvania Perelman School of Medicine...
